Zhongchao Li

Apr 15, 2024 | nature.com | Zhongchao Li |Bo Zhang |Xuetao Shi |Kai Cui |Zhicheng Sun |Mingming Li | +3 more

AbstractNotable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC of BCLC stage 0-A received 3\(\times \) Gy SBRT and two cycles of tislelizumab, an anti-PD-1 monoclonal antibody before the curative HCC resection.

Apr 12, 2024 | onlinelibrary.wiley.com | Rongzhu Liang |Zhiwei Zhang |Jin Wu |Zhongchao Li

CONFLICT OF INTEREST STATEMENT The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors have read and approve this paper, and due care has been taken to ensure the integrity of the work. Neither the entire paper nor any part of its content has been published or has been accepted elsewhere, and it is not being submitted to any other journal. REFERENCES 1, , , .